Victory Capital Management
ANIX icon

Victory Capital Management’s Anixa Biosciences ANIX Stock Holding History

Victory Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,212
Closed -$12K – 2537
2020
Q1 		$12K Buy
+7,212
New +$21.1K ﹤0.01% 3242
2019
Q4 		– Sell
-3,534
Closed -$14K – 2659
2019
Q3 		$14K Buy
+3,534
New +$14.8K ﹤0.01% 3148

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Victory Capital Management's ANIX Position: Q2 2020 in Review

Victory Capital Management sold out of Anixa Biosciences (ANIX) in Q2 2020, closing a stake of 7,212 shares — an estimated $12K sold.

Victory Capital Management first reported a position in ANIX in Q3 2019 and held it in 2 quarters. The position peaked at $14K in Q3 2019. 19 funds tracked by Wall St. Rank hold ANIX as of Q2 2020.

  • Victory Capital Management reported no remaining Anixa Biosciences position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 7,212 Anixa Biosciences shares in Q2 2020, an estimated $12K.
  • Victory Capital Management first reported a position in Anixa Biosciences in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's Anixa Biosciences position peaked at $14K in Q3 2019.
  • 19 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.